Biogen (BIIB) Competitors $146.47 -0.92 (-0.62%) (As of 12/20/2024 05:45 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends BIIB vs. REGN, ALNY, UTHR, INCY, NBIX, BMRN, EXAS, EXEL, RGEN, and MDGLShould you be buying Biogen stock or one of its competitors? The main competitors of Biogen include Regeneron Pharmaceuticals (REGN), Alnylam Pharmaceuticals (ALNY), United Therapeutics (UTHR), Incyte (INCY), Neurocrine Biosciences (NBIX), BioMarin Pharmaceutical (BMRN), Exact Sciences (EXAS), Exelixis (EXEL), Repligen (RGEN), and Madrigal Pharmaceuticals (MDGL). These companies are all part of the "biotechnology" industry. Biogen vs. Regeneron Pharmaceuticals Alnylam Pharmaceuticals United Therapeutics Incyte Neurocrine Biosciences BioMarin Pharmaceutical Exact Sciences Exelixis Repligen Madrigal Pharmaceuticals Biogen (NASDAQ:BIIB) and Regeneron Pharmaceuticals (NASDAQ:REGN) are both large-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, media sentiment, risk, valuation, community ranking, institutional ownership, profitability, dividends and analyst recommendations. Which has higher earnings and valuation, BIIB or REGN? Regeneron Pharmaceuticals has higher revenue and earnings than Biogen. Biogen is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBiogen$9.61B2.22$1.16B$11.0713.23Regeneron Pharmaceuticals$13.85B5.57$3.95B$40.4117.37 Does the MarketBeat Community favor BIIB or REGN? Biogen received 267 more outperform votes than Regeneron Pharmaceuticals when rated by MarketBeat users. Likewise, 71.76% of users gave Biogen an outperform vote while only 66.99% of users gave Regeneron Pharmaceuticals an outperform vote. CompanyUnderperformOutperformBiogenOutperform Votes180771.76% Underperform Votes71128.24% Regeneron PharmaceuticalsOutperform Votes154066.99% Underperform Votes75933.01% Is BIIB or REGN more profitable? Regeneron Pharmaceuticals has a net margin of 33.61% compared to Biogen's net margin of 16.81%. Regeneron Pharmaceuticals' return on equity of 16.88% beat Biogen's return on equity.Company Net Margins Return on Equity Return on Assets Biogen16.81% 14.98% 8.59% Regeneron Pharmaceuticals 33.61%16.88%13.23% Which has more volatility and risk, BIIB or REGN? Biogen has a beta of -0.08, indicating that its stock price is 108% less volatile than the S&P 500. Comparatively, Regeneron Pharmaceuticals has a beta of 0.08, indicating that its stock price is 92% less volatile than the S&P 500. Do institutionals & insiders have more ownership in BIIB or REGN? 87.9% of Biogen shares are held by institutional investors. Comparatively, 83.3% of Regeneron Pharmaceuticals shares are held by institutional investors. 0.2% of Biogen shares are held by insiders. Comparatively, 7.5% of Regeneron Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Does the media refer more to BIIB or REGN? In the previous week, Regeneron Pharmaceuticals had 11 more articles in the media than Biogen. MarketBeat recorded 28 mentions for Regeneron Pharmaceuticals and 17 mentions for Biogen. Regeneron Pharmaceuticals' average media sentiment score of 0.48 beat Biogen's score of 0.11 indicating that Regeneron Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Biogen 3 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 4 Negative mention(s) 1 Very Negative mention(s) Neutral Regeneron Pharmaceuticals 8 Very Positive mention(s) 4 Positive mention(s) 11 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts recommend BIIB or REGN? Biogen currently has a consensus target price of $242.68, suggesting a potential upside of 65.69%. Regeneron Pharmaceuticals has a consensus target price of $1,052.90, suggesting a potential upside of 50.02%. Given Biogen's higher probable upside, analysts clearly believe Biogen is more favorable than Regeneron Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biogen 0 Sell rating(s) 16 Hold rating(s) 13 Buy rating(s) 0 Strong Buy rating(s) 2.45Regeneron Pharmaceuticals 1 Sell rating(s) 6 Hold rating(s) 15 Buy rating(s) 1 Strong Buy rating(s) 2.70 SummaryRegeneron Pharmaceuticals beats Biogen on 15 of the 19 factors compared between the two stocks. Ad Crypto 101 MediaThis Crypto Is Set to Explode in DecemberIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this surge is a massive new blockchain development…YES, I WANT THE #1 CRYPTO NOW Get Biogen News Delivered to You Automatically Sign up to receive the latest news and ratings for BIIB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BIIB vs. The Competition Export to ExcelMetricBiogenBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$21.34B$2.94B$5.14B$9.08BDividend YieldN/A1.90%5.09%4.23%P/E Ratio13.2345.9489.7417.16Price / Sales2.22415.011,117.09117.04Price / Cash8.54182.1043.1037.86Price / Book1.433.894.784.78Net Income$1.16B-$42.21M$120.31M$225.60M7 Day Performance-2.37%-2.15%-1.92%-1.23%1 Month Performance-7.24%1.73%13.65%0.46%1 Year Performance-43.22%16.36%28.34%15.24% Biogen Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BIIBBiogen4.6286 of 5 stars$146.47-0.6%$242.68+65.7%-42.3%$21.34B$9.61B13.237,570Analyst DowngradeHigh Trading VolumeREGNRegeneron Pharmaceuticals4.6619 of 5 stars$736.21+0.7%$1,099.90+49.4%-16.6%$80.90B$13.12B18.1013,450Analyst ForecastALNYAlnylam Pharmaceuticals4.4122 of 5 stars$245.340.0%$298.09+21.5%+35.5%$31.64B$1.83B-93.682,100Analyst UpgradeUTHRUnited Therapeutics4.7048 of 5 stars$368.83+1.9%$370.86+0.5%+64.7%$16.47B$2.76B16.221,168Analyst DowngradeInsider TradePositive NewsINCYIncyte4.7049 of 5 stars$69.95+2.0%$76.13+8.8%+11.6%$13.48B$4.08B489.642,524Analyst ForecastNBIXNeurocrine Biosciences4.8286 of 5 stars$132.88+4.9%$165.00+24.2%+11.8%$13.45B$2.24B35.791,400Analyst ForecastInsider TradePositive NewsBMRNBioMarin Pharmaceutical4.9845 of 5 stars$66.66+1.0%$94.20+41.3%-31.0%$12.70B$2.75B39.533,401Positive NewsEXASExact Sciences4.4883 of 5 stars$60.87-0.6%$72.94+19.8%-16.8%$11.27B$2.50B-52.356,600EXELExelixis4.5006 of 5 stars$35.81+2.2%$31.47-12.1%+41.8%$10.23B$2.08B22.461,310Analyst DowngradeAnalyst RevisionRGENRepligen4.1003 of 5 stars$158.15+1.1%$190.25+20.3%-20.7%$8.86B$639.92M-422.731,783Analyst ForecastPositive NewsMDGLMadrigal Pharmaceuticals4.2319 of 5 stars$308.14+1.2%$347.33+12.7%+38.7%$6.72BN/A-12.1490Positive News Related Companies and Tools Related Companies Regeneron Pharmaceuticals Competitors Alnylam Pharmaceuticals Competitors United Therapeutics Competitors Incyte Competitors Neurocrine Biosciences Competitors BioMarin Pharmaceutical Competitors Exact Sciences Competitors Exelixis Competitors Repligen Competitors Madrigal Pharmaceuticals Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:BIIB) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersThis Crypto Is Set to Explode in DecemberIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredAI breakthrough about to upend industryEveryone is talking about AI right now. The talk has been endless ever since ChatGPT was released to the m...Porter & Company | SponsoredNvidia’s Bold Move: Tackling Tech’s $1 Trillion CrisisTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | SponsoredYour bank is lying to you.You might think you have your money in a high-yield savings account, but do you really? The national average A...MyBankTracker | SponsoredMUST SEE: The most important video in the world right now?If you have a significant amount of money in the stock market right now — or if you're sitting on the sideline...InvestorPlace | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAltcoin season moves fast, and those who hesitate are left behind. The window is closing.Crypto Swap Profits | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Biogen Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Biogen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free BIIB Stock Alerts